Designed multiple ligands. An emerging drug discovery paradigm.
about
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasisDeveloping dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxideDrug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening MethodologiesDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersStructure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problemMechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosisStructure and inhibition of subunit I of the anthranilate synthase complex of Mycobacterium tuberculosis and expression of the active complexA ranking method for the concurrent learning of compounds with various activity profiles.Creation of a free, Internet-accessible database: the Multiple Target Ligand DatabaseEpigenetic polypharmacology: from combination therapy to multitargeted drugsMechanistic and functional differentiation of tapentadol and tramadolStabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancerWhich compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical developmentKetoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrationsDistribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discoveryMemoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's diseaseMethod for comparing the structures of protein ligand-binding sites and application for predicting protein-drug interactions.Identification of diaryl 5-amino-1,2,4-oxadiazoles as tubulin inhibitors: the special case of 3-(2-fluorophenyl)-5-(4-methoxyphenyl)amino-1,2,4-oxadiazoleAutomated design of ligands to polypharmacological profiles.Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTRWhat is next for small-molecule drug discovery?Potential strategies for increasing drug-discovery productivity.Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity.Potentiating Metronidazole Scaffold against Resistant Trichomonas: Design, Synthesis, Biology and 3D-QSAR Analysis.The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserineCharacterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases.Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide.Bi- or multifunctional opioid peptide drugs.Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers.Anti-leukemia activity of a Hsp70 inhibitor and its hybrid moleculesEfficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).Rationally designed multitarget agents against inflammation and pain.Synergistic inhibitory effect of berberine and d-limonene on human gastric carcinoma cell line MGC803.Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillaminesDiscovery of 3-Arylcoumarin-tetracyclic Tacrine Hybrids as Multifunctional Agents against Parkinson's DiseaseFentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.Naturally occurring multipotent anti-Alzheimer's agents.
P2860
Q23913301-7C5EA350-09A0-46E0-9949-159A7EDE43DBQ24321779-C8F4A869-BD5E-4990-A2AA-332A81FA5A0EQ26745421-CA025283-9C3D-48C2-A790-F7FF30A97716Q26748728-C8947FB3-50A7-4FD9-BC6D-25E1DE4FE447Q26829549-24807782-2DA7-414A-9227-317D405DD6B6Q27653610-D12C5486-6AA4-4BE0-801D-930146DC4A2EQ27702561-7EB91D23-80F1-4A02-9D5F-1C8945A738A6Q27902271-EE12F997-BDDA-4DD6-B749-BB0BAEF719BBQ27902291-DFBF7717-208C-4486-A995-AE1AB64A4208Q28067666-2EDFF0BE-3CC8-4BC3-AD34-40298380CDB7Q28268772-5139F5F3-46ED-4D74-987F-203E1F67F17EQ28304230-1094466F-48C5-46AC-BBC5-545147CFF0F0Q28478130-E824E486-AF6C-4A34-BEF3-F3D34E09F3F3Q28539116-96BA42CB-16AC-4570-AA0E-367C6052E400Q28754659-17B96FFC-7D2E-4842-8780-F5BC45ED513BQ28820783-238A4CAA-33D2-495C-83D7-BEE2BB019208Q30367299-A1ADB64E-B7A6-42C5-9350-96D012AD092BQ30414464-DB3174B1-449C-4D89-A460-147CEB687945Q30539786-51D7C120-0F27-4A11-8A37-05368FA618CAQ30940037-5494E1E9-C518-4221-87EE-8BD6CBC784A0Q31004268-815381B0-A39F-4742-AA39-EEEB3F08E229Q31154360-1D255885-00A8-48BF-914B-9D05F612D5A1Q33598615-A061F069-3E9C-4B52-BB47-E188EFDC188DQ33630457-5EAF9EBE-4CE7-4910-97CB-6AA7EFE62331Q33630562-3B5D4A50-E0B5-4648-A66E-C210F6887CE4Q33635987-4E6E7533-1C85-4ECB-A3AB-AD9F4EBB633EQ33687059-22E009EF-438B-4405-BE17-AC0B5BFFE954Q33754704-B623EEFC-BAC5-4AFA-902A-6BC13859C5D8Q33767037-D43BB426-964B-4DE1-80AA-9C3FA300A3AFQ33768567-A3C80855-844C-4BFD-94AF-13AF743A8672Q33799516-939832FF-09FE-4030-86FD-552AE968519DQ33868254-32D34CED-EDC6-4D02-9523-B5A0D265CE29Q33926350-6A695316-F53E-4B5D-8867-7D050CE75DDCQ33960685-16202431-AA5F-4A37-8AC5-44D472E94383Q34124618-2BFFB96C-CE1D-41EE-8C7C-EC3CC13D338FQ34145341-FC95E1CB-A281-4785-B7DF-8D8A94199E81Q34310215-D9D4E5E1-D20B-45F2-923A-AB07BED56868Q34410429-93148B37-98A8-4765-BFBD-DCEAB890153FQ34591673-44494A37-855E-454D-B58F-2C5ED6749BE3Q34621248-0D56E18C-0275-4BC4-A438-E591A19EB987
P2860
Designed multiple ligands. An emerging drug discovery paradigm.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Designed multiple ligands. An emerging drug discovery paradigm.
@ast
Designed multiple ligands. An emerging drug discovery paradigm.
@en
type
label
Designed multiple ligands. An emerging drug discovery paradigm.
@ast
Designed multiple ligands. An emerging drug discovery paradigm.
@en
prefLabel
Designed multiple ligands. An emerging drug discovery paradigm.
@ast
Designed multiple ligands. An emerging drug discovery paradigm.
@en
P356
P1476
Designed multiple ligands. An emerging drug discovery paradigm.
@en
P2093
Richard Morphy
Zoran Rankovic
P304
P356
10.1021/JM058225D
P407
P577
2005-10-01T00:00:00Z